home / stock / qdel / qdel articles
QuidelOrtho Corp (NASDAQ: QDEL) is reportedly contemplating the potential sale of its transfusion medicine arm. The diagnostics company is cur...
QuidelOrtho Corporation (NASDAQ: QDEL) released preliminary Q3 revenue of $738 million to $744 million, primarily driven by higher respir...
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVI...
News, Short Squeeze, Breakout and More Instantly...
Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600 Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600 PR Newswire NEW YORK , July 23, 2024 /PRNewswir...
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financ...
2024-07-09 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...